New Concepts Relating Mesenchymal Tumors Based on Genetics and Epigenetics

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Microenvironment".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 752

Special Issue Editor

1. Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
2. Diagnostic Laboratory, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
Interests: mesenchymal tumors; soft tissue; sarcoma; genetics; epigenetics

Special Issue Information

Dear Colleagues,

With the rapid development of new molecular techniques, we are able to reappraise our conventional classification system of soft tissue tumors, at least for certain tumor groups. Moreover, we are responsible for the development of new concepts.

A new classification mainly based on molecular findings may help treat patients better and collect adequate data of larger cohorts to understand the underlying biology and improve the therapy and assessment of prognosis.

In this Special Issue, we discuss categories of tumors, often selected in small groups based on clinicopathological findings, including immunohistochemistry, and wish to demonstrate that it would be useful to re-classify them due to the same genetic pathways and epigenetic findings leading to a more proper classification with clinical implications.

Dr. Uta Flucke
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mesenchymal tumors
  • soft tissue
  • sarcoma
  • genetics
  • epigenetics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 785 KiB  
Review
Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma
by Vincenzo Ingangi, Annarosaria De Chiara, Gerardo Ferrara, Michele Gallo, Antonio Catapano, Flavio Fazioli, Gioconda Di Carluccio, Elisa Peranzoni, Ilaria Marigo, Maria Vincenza Carriero and Michele Minopoli
Cells 2024, 13(11), 977; https://doi.org/10.3390/cells13110977 - 4 Jun 2024
Viewed by 590
Abstract
Chondrosarcoma (ChS), a malignant cartilage-producing tumor, is the second most frequently diagnosed osseous sarcoma after osteosarcoma. It represents a very heterogeneous group of malignant chemo- and radiation-resistant neoplasms, accounting for approximately 20% of all bone sarcomas. The majority of ChS patients have a [...] Read more.
Chondrosarcoma (ChS), a malignant cartilage-producing tumor, is the second most frequently diagnosed osseous sarcoma after osteosarcoma. It represents a very heterogeneous group of malignant chemo- and radiation-resistant neoplasms, accounting for approximately 20% of all bone sarcomas. The majority of ChS patients have a good prognosis after a complete surgical resection, as these tumors grow slowly and rarely metastasize. Conversely, patients with inoperable disease, due to the tumor location, size, or metastases, represent a great clinical challenge. Despite several genetic and epigenetic alterations that have been described in distinct ChS subtypes, very few therapeutic options are currently available for ChS patients. Therefore, new prognostic factors for tumor progression as well as new treatment options have to be explored, especially for patients with unresectable or metastatic disease. Recent studies have shown that a correlation between immune infiltrate composition, tumor aggressiveness, and survival does exist in ChS patients. In addition, the intra-tumor microvessel density has been proven to be associated with aggressive clinical behavior and a high metastatic potential in ChS. This review will provide an insight into the ChS microenvironment, since immunotherapy and antiangiogenic agents are emerging as interesting therapeutic options for ChS patients. Full article
Show Figures

Figure 1

Back to TopTop